This supports the use of PPARγ agonists, such as rosiglitazone and pioglitazone, in managing diabetes and obesity in atherosclerosis patients (Ryan et al., 2007; Powell et al., 2012). Here, PPARG is linked to obesity due to melanocortin 4 receptor deficiency.